UCB, a global biopharmaceutical company, has unveiled the findings of 48-week post-hoc analyses derived from pooled Phase 3 data originating from the BE HEARD I and BE HEARD II trials. These analyses scrutinized the influence of bimekizumab on skin pain…
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a pioneer in RNAi therapeutics, has announced positive results from the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for treating hypertension. The study met its primary endpoint, demonstrating…
Argonaut Manufacturing Services Secures $45M Funding for Expanded Pharma Fill / Finish Facility Argonaut Manufacturing Services, a prominent contract development and manufacturing organization in the biopharma and life sciences sectors, has finalized a $45 million financing deal to bolster its…
Aktana Unveils “Aktana for MedTech” to Revolutionize HCP Engagement Aktana, the forefront in intelligent customer engagement for global life sciences and the medical sector, has introduced “Aktana for MedTech.” This groundbreaking set of tools leverages AI to optimize field representative…
Summit Therapeutics (NASDAQ: SMMT) will present at the Barclays 26th Global Healthcare Conference in Miami Beach, FL from March 12-14, 2024. CEO Dr. Maky Zanganeh and Chairman Robert W. Duggan will discuss the innovative investigational bispecific antibody, ivonescimab, on March…
ResearchAndMarkets.com is pleased to announce the addition of the “FARXIGA Market Size, Forecast, and Emerging Insight – 2032” report to its offerings. This comprehensive report delves into the impact and projected growth of FARXIGA in the treatment landscape of myocardial…
Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has revealed that Jannie Oosthuizen, President of Human Health U.S., is set to engage in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on…
Transgene (Euronext Paris: TNG), a biotechnology company specializing in virus-based immunotherapies for cancer treatment, NEC Corporation (NEC; TSE: 6701), a leader in IT, network, and AI technologies, and BostonGene Corporation (BostonGene), a prominent AI-based molecular and immune profiling firm, have…
United Therapeutics Corporation (Nasdaq: UTHR), a leading public benefit corporation, has disclosed that Patrick Poisson, Executive Vice President of Technical Operations, will participate in a fireside chat session at the Leerink Partners Global Biopharma Conference 2024 in Miami Beach, Florida.…
Epsilogen and Lonza Achieve Breakthrough in Manufacturing IgE Antibody for Ovarian Cancer Treatment Epsilogen, a leader in developing IgE antibodies for cancer therapy, and Lonza, a global partner in pharmaceutical manufacturing, have announced the successful completion of Good Manufacturing Practice…
Shionogi & Co., Ltd. (Headquartered in Osaka, Japan; CEO: Isao Teshirogi, Ph.D.; referred to as “Shionogi” hereafter) has initiated the second phase of collaboration with Nagasaki University (Located in Nagasaki, Nagasaki Prefecture; President: Takeshi Nagayasu), focusing on comprehensive cooperation in…
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) has initiated dosing for the first patient in the STARLIGHT™ 2 Phase 3 pivotal study for fezolinetant, an investigational oral, nonhormonal compound aimed at addressing vasomotor symptoms (VMS) linked…